BOULDER, Colo. (AP) _ Array BioPharma Inc. (ARRY) on Tuesday reported a loss of $37.5 million in its fiscal third quarter.
On a per-share basis, the Boulder, Colorado-based company said it had a loss of 17 cents.
The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 21 cents per share.
The drug developer posted revenue of $64.7 million in the period, also beating Street forecasts. Six analysts surveyed by Zacks expected $51.5 million.
Array BioPharma shares have increased 62% since the beginning of the year. The stock has risen 69% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ARRY at https://www.zacks.com/ap/ARRY